RAS-targeted therapies: is the undruggable drugged?

AR Moore, SC Rosenberg, F McCormick… - Nature reviews Drug …, 2020 - nature.com
Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …

The path to the clinic: a comprehensive review on direct KRASG12C inhibitors

AK Kwan, GA Piazza, AB Keeton, CA Leite - Journal of Experimental & …, 2022 - Springer
The RAS oncogene is both the most frequently mutated oncogene in human cancer and the
first confirmed human oncogene to be discovered in 1982. After decades of research, in …

[HTML][HTML] Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy

TC Yu, F Guo, Y Yu, T Sun, D Ma, J Han, Y Qian… - Cell, 2017 - cell.com
Gut microbiota are linked to chronic inflammation and carcinogenesis. Chemotherapy failure
is the major cause of recurrence and poor prognosis in colorectal cancer patients. Here, we …

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies

J Zhou, Q Ji, Q Li - Journal of Experimental & Clinical Cancer Research, 2021 - Springer
Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth
factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC) …

Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists …

AR Sepulveda, SR Hamilton, CJ Allegra… - American journal of …, 2017 - academic.oup.com
Objectives: To develop evidence-based guideline recommendations through a systematic
review of the literature to establish standard molecular biomarker testing of colorectal cancer …

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer

KC Arbour, E Jordan, HR Kim, J Dienstag, HA Yu… - Clinical Cancer …, 2018 - AACR
Purpose: KRAS mutations occur in approximately 25% of patients with non–small cell lung
cancer (NSCLC). Despite the uniform presence of KRAS mutations, patients with KRAS …

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

M Román, I Baraibar, I López, E Nadal, C Rolfo… - Molecular cancer, 2018 - Springer
Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …

Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer

SS Fois, P Paliogiannis, A Zinellu, AG Fois… - International journal of …, 2021 - mdpi.com
Lung cancer is the leading cause of death for malignancy worldwide. Its molecular profiling
has enriched our understanding of cancer initiation and progression and has become …

[HTML][HTML] KRAS-Mutant non-small cell lung cancer: From biology to therapy

I Ferrer, J Zugazagoitia, S Herbertz, W John… - Lung cancer, 2018 - Elsevier
In patients with non-small cell lung cancer (NSCLC), the most frequent oncogene driver
mutation in Western countries is Kirsten rat sarcoma viral oncogene homolog (KRAS), and …

[HTML][HTML] Circulating biomarkers for early detection and clinical management of colorectal cancer

M Marcuello, V Vymetalkova, RPL Neves… - Molecular Aspects of …, 2019 - Elsevier
New non-invasive approaches that can complement and improve on current strategies for
colorectal cancer (CRC) screening and management are urgently needed. A growing …